

Author Index Volume 60 July-December 1999

Affandi, B., 281
Aisien, A.O., 249
Alvarado, G., 45
Amaral, E., 361
Andersen, L.F., 337
Arbogast, K., 15
Archer, D.F., 15, 151
Arévalo, M., 65, 357
Aura, M., 243

Baker, J., 15
Ballagh, S.A., 255
Bangou, J., 167
Bassol, S., 45
Bastola, S., 31
Bhattacharai, L., 31
Bradshaw, K.D., 255
Brandao, M.A.F., 305
Bravo, C., 9

Calaf, J., 243
Callahan, M.M., 15, 71
Carlos, G., 45
Casado, M.E., 9
Chanda, O., 9
Chasan-Taber, L., 145
Chaudhary, I., 39
Chen-Mok, M., 15, 155
Christiansen, E., 337
Clark, S., 223
Clark, V.A., 289
Creinin, M.D., 263
Cromie, M.A., 179, 201
Croxatto, H.B., 9
Curhan, G.C., 145

Day, J., 31
Delgado, S.R., 233
Di, X., 161
Diaz, S., 9, 45
Dominik, R., 71, 315
Dusterberg, B., 269

Edgren, R.A., 313
El-Husseini, M., 87, 93, 101
Ellertson, C., 119, 167, 223, 233
El-Nahal, N., 87, 93, 101
Elomaa, K., 275, 299
Elul, B., 167, 223, 233
Endrikat, J., 269
Espins, J.J., 243

Faúndes, A., 361
FemCap Investigators' Group,
The, 71
Fernandez, V., 45
Fetis, G., 9
Fong, Y.-F., 51, 173
Frezieres, R.G., 289

Gabelnick, H.L., 15
Garceau, R.J., 179
Garcia-Barrios, C., 233
Garg, S., 361
Gerlinger, C., 269
Gispert, M., 243
Goco, N., 345
Godwin, A.J., 81
Gonzalez, B., 345
Goyaux, N., 107
Grimes, D.A., 57
Gu, S., 161
Guengant, J.-P., 167
Guerra, M.O., 305
Guful, F., 249

Harper, C., 233
Hassan, E.O., 87, 93, 101
Heimburger, A., 233
Hertz-Pannier, I., 137
Hopkins, N.K., 201, 209
Hubacher, D., 345

Inayatullah, A., 39

Jain, S., 111
Jain, J.K., 353
Jaisamraun, U., 25
Jennings, V., 65, 357
Jespersen, J., 337
Jha, R., 31
Jiang, J., 161
Juhakoski, A., 299

Kaewrudee, S., 25
Kaper, R.F., 1
Kaunitz, A.M., 177, 179
Koide, S.S., 111
Korver, T., 281
Kumar, P.G., 111

Lahteenmaki, P., 275, 299
LaLoraya, M., 111
Langer, A., 233

Lavin, P., 9
Ledesma, L., 45
Li, Y., 161
Lippman, J.S., 81
Liu, C.Q., 309
Lu, S.H., 309
Lukhando, M., 223
Lunelle Study Group, The, 179

Madsbad, S., 337
Mant, J., 331
Massai, R., 9
Mauck, C., 15, 71
Mazoni, A.S.B., 305
McMullen, S., 31, 155
Meckstroth, K.R., 353
Meyers, A., 321
Miranda, P., 9
Mishell, Jr., D.R., 177, 353
Moo-Young, A., 299
Morales, E., 45
Morrison, C.S., 15
Muia, E., 223
Mutahir, J.T., 249

Nelson, A.L., 289
Nichols, M., 255

Oleen-Burkey, M., 215
Olenja, J., 223
Olson, W., 81

Painter, R., 353
Park, M., 353
Peralta, O., 9
Peters, V.M., 305
Petersen, K.R., 337
Pymar, H.C., 263

Qian, S.-Z., 1

Rahimy, M.H., 189, 201, 209
Rai, C., 31
Raymond, E., 45, 137
Redmond, G., 81
Rehan, N., 39
Reinprayoon, D., 25
Rivera, R., 31, 155
Rodreguez-Espinosa, J., 243
Rosenberg, M.J., 321
Roy, V., 321
Ruebig, A., 269

Ryan, K.K., 189, 209
Saleh, S.I., 299
Sang, G.W., 1
Saxena, D., 111
Schiavon, R., 233
Schoenbach, V., 137
Schulz, K.F., 57
Schwartz, J.L., 263
Shrestha, S., 31
Shulman, L.P., 215
Silva, M.A., 9
Sinai, I., 65, 357
Singh, K., 51, 173
Skouby, S.O., 337
Sonosiain, R., 243
Stampfer, M.J., 145
Stanczyk, F.Z., 255, 313
Steiner, M., 137
Stock, R., 15
Strowitzki, T., 281
Suherman, S.K., 281
Suvisaari, J., 299
Taneepanichskul, S., 25
Taylor, D., 345
Thadhani, R., 145
Thapa, S., 31
Thonneau, P., 107
Thorneycroft, I.H., 255
Tong, D.M., 201
Trussell, J., 119, 137, 315
Ujah, I.A.O., 249
Vald, S.P., 9
Vanrell, C., 243
Veazey, R., 15
Vega, C., 243
Vessey, M., 331
Waller, D., 361
Walsh, T.L., 289, 315
Wang, Z.X., 309
Weber, M.E., 255
Weiner, D.H., 71
Welffens-Ekra, C., 107
Wheless, A., 137
Wilke, R.J., 215
Willett, W.C., 145
Wraxall, B.G.D., 289
Yac-Soumah, F., 107
Yuan, Y., 309
Zanevald, L., 361
Zepeda, A., 9
Zhang, C., 161
Zheng, S.-R., 1
Zheng, H.-M., 1
Zhiying, P., 15

Subject Index Volume 60 July-December 1999

Abortion practices, complications, 107
Acceptability, nonoxynol-9 spermicide preparations, 45
Acceptability and satisfaction, Lunelle™, 177
Acidform,
acid-buffering bioadhesive gel, 361
vaginal tolerance, 361
Acne,
effect of ethinyl estradiol + levonorgestrel, 255
effect of ethinyl estradiol + norethindrone acetate, 255
effect of ethinyl estradiol + norgestimate, 81
Adenomyosis, treatment with levonorgestrel-releasing IUD, 173
Androgens, effect of OCs, 255
Anemia, prevalence in family planning clinics, 93
Antibiotic prophylaxis, IUD insertion, 57
Antiestrogens, effect on uterine activity, 111
Attitudes about emergency contraception, 223, 233

Back disorders, effect of OC use, 331
Barrier contraceptive, FemCap®, 71
Bone density, effect of levonorgestrel, 161
Bone metabolism, effect of levonorgestrel, 161

Cervical ectopy, effect of DMPA, 19
Checklist, safe initiation of DMPA, 31
Client characteristics, effect on TCu 380A discontinuations, 155
Clinical study,
Cyclofem, 87
ethinyl estradiol + desogestrel, 269
Implanon implant, 1
Mesigyna, 87
Norplant implants, 1, 39
progesterone-releasing vaginal ring, 9
Clinical trial,
Lunelle, 177, 179, 189, 201, 209, 215
medical abortion regimens, 119
Coital frequency, influence on risk of pregnancy, 137
Commentary, gonane progestins nomenclature, 313
Complications, induced abortion methods, 107
Condom failure, detection of PSA, 289
Continuation rates,
DMPA users, 345
Norplant implants, 39
Contraceptive failure rates, perfect users vs. perfect use, 315
Cost-effectiveness analysis, trimonthly OC regimen, 263

Cycle variability, influence on risk of pregnancy, 137
Cyclofem®, clinical study, 87

Depot-medroxyprogesterone acetate (DMPA), effect on vaginal epithelium and cervical ectopy, 15
Diaphragm, Ortho All-Flex, 71
Discontinuation reasons, use of TCu 380A, 155
DMPA (depot-medroxyprogesterone acetate)
DMPA + estradiol cypionate, 177, 179, 189, 201, 209, 215
DMPA initiation, checklist for safe delivery, 31
DMPA users, continuation rates, 345

Effectiveness, postcoital contraception, 201
Efficacy, medical abortion, 119
Embryo toxicity, lapachol (rat), 305
Emergency contraception,
ethinyl estradiol + levonorgestrel, 243
knowledge, attitudes and practices, 223, 233
Endometrial histology, effect of ethinyl estradiol + desogestrel, 151
Estradiol,
effect on uterine activity, 111
pharmacokinetics, 209
Ethinyl estradiol + desogestrel,
clinical study, 132, 269
effect on endometrial histology, 151
Ethinyl estradiol + gestodene,
clinical study, 269
effect on insulin sensitivity, 337
ovulatory potential of follicles, 275
Ethinyl estradiol + levonorgestrel,
clinical study, 321
effect on androgen profile, 255
postcoital contraception, 243
Ethinyl estradiol + norethindrone, clinical study, 179
Ethinyl estradiol + norgestimate,
clinical study, 321
effect on insulin sensitivity, 337
treatment of acne vulgaris, 81
Extended use of OC pills, cost-effectiveness analysis, 263

Failure rates, perfect users vs. perfect use, 137
Family planning clinics, prevalence of anemia, 93
Female condom study, 137
Female sterilization, minilaparotomy, 249
FemCap®, safety and efficacy, 71
Ferritin level,
effect of combined OC, 101

effect of TCu 380A, 101
 Fertile window,
 fixed formula, 357
 use of TwoDay Algorithm, 65

Gestational hypertensive disorders, effect of pregravid OC use, 145
 Gonane progestins, nomenclature, 313
 Gynefix®, late uterine perforation, 55
 Hemoglobin level,
 effect of combined OC, 101
 effect of TCu 380A

Identify fertile window,
 fixed formula, 12-5
 use of TwoDay Algorithm, 65
 Implanon® implant,
 clinical study, 1
 Implant contraceptive,
 etonogestrel, 1, 281
 levonorgestrel, 1, 25, 39, 161, 281
 Injectable contraceptive,
 depot-medroxyprogesterone acetate, 15, 31, 345
 DMPA + estradiol cypionate, 87, 177, 179, 189, 201, 209, 215
 norgestimate + estradiol valerate, 87
 Insulin sensitivity, OC users, 337
 Interceptive effect, lapachol (rat), 305
 Intrauterine device (IUD),
 Gynefix, 55
 Multiload Cu 250, 281
 TCu 380A, 9, 101, 155
 IUD (intrauterine device)
 IUD insertion, prophylactic antibiotics, 1
 IUD use, effect on back disorders, 331
 IUS (intrauterine system)

Knowledge level, emergency contraception, 223, 233

Lapachol, interceptive effect (rat), 305
 Late onset of OC treatment, effect on ovulatory potential of follicles, 275
 Levonorgestrel-releasing IUS,
 effect on uterine myomas, 51
 treatment of adenomyosis, 173
 Lipid metabolism,
 effect of etonogestrel, 281
 effect of levonorgestrel, 281
 effect of Multiload Cu 250, 281
 Lunelle™, clinical trial, 177, 179, 189, 201, 209, 215

Male subdermal implants, 7 α -methyl-19-nortestosterone, 299
 Medical abortion,
 efficacy, 119
 mifepristone + misoprostol, 167
 misoprostol, 353
 tamoxifen + misoprostol, 353
 Medical abortion methods, 119

Medroxyprogesterone acetate, pharmacokinetics, 201, 209
 Mefenamic acid, effect on irregular uterine bleeding, 25
 Mesigyna®, clinical study, 87
 7 α -Methyl-19-nortestosterone, pharmacokinetics, 299
 Mifepristone, effect on uterus (rabbit), 309
 Mifepristone + misoprostol, medical abortion, 167
 Minilaparotomy, female sterilization, 249
 Misoprostol, medical abortion, 353
 Multiload Cu 250, effect on lipid metabolism, 281

Natural family planning,
 fixed formula to define fertile window, 357
 use of TwoDay Algorithm, 65
 Nonoxynol-9 film, acceptability, 45
 Nonoxynol-9 tablet, acceptability, 45
 Norplant® implants,
 clinical study, 1, 39
 effect on lipid metabolism, 281
 effects on bone density and bone metabolism, 161
 irregular uterine bleeding, 25
 Nursing women, progesterone-releasing vaginal ring, 9

OC (oral contraceptive)
 OC trial, use of placebo control, 81
 OC use,
 effect on back disorders, 331
 effect on hemoglobin and ferritin levels, 101
 risk of gestational hypertensive disorders, 145
 OC users,
 stroke risk, 177
 Europe vs. US studies, 177
 OCs and insulin sensitivity, 337
 Oral contraceptive (OC),
 ethinyl estradiol + desogestrel, 151, 269
 ethinyl estradiol + gestodene, 269, 275
 ethinyl estradiol + levonorgestrel, 255
 ethinyl estradiol + norethindrone acetate, 255
 triphasic ethinyl estradiol + gestodene, 337
 triphasic ethinyl estradiol + norethindrone, 179
 triphasic ethinyl estradiol + norgestimate, 81, 12-3
 Ortho All-Flex®, safety and efficacy, 71
 Ovarian function, effect of DMPA + estradiol cypionate, 189
 Ovulatory potential of follicles, effect of ethinyl estradiol + gestodene, 275

Perfect users vs. perfect use, risk of pregnancy, 315
 Pharmacodynamic effects, DMPA + estradiol cypionate, 189
 Pharmacokinetics,
 estradiol, 209
 medroxyprogesterone acetate, 201, 209
 7 α -methyl-19-nortestosterone, 299
 Placebo controls, use in OC trial, 81

Postcoital contraception, ethinyl estradiol + levonorgestrel, 243

Pregnancy risk, influence of cycle variability and coital frequency, 137
perfect users vs. perfect use, 315

Pregravid OC use, effect on gestational hypertensive disorders, 145

Progesterone-releasing vaginal ring, clinical study, 9

Progestins nomenclature, commentary, 313

Prostate specific antigen (PSA), semen marker of condom failure, 289

PSA (prostate specific antigen) 289

Return of ovulation, following DMPA + estradiol cypionate, 189

Safe delivery of DMPA, use of checklist, 31

Semen biomarker, prostate specific antigen, 289

Spermicide, nonoxynol-9, 45

Stroke risk, OC users, 177

Subdermal implants (male), 7 α -methyl-19-nortestosterone, 299

Tamoxifen + misoprostol, medical abortion, 353

TCu 380A, clinical study, 9
effect on hemoglobin and ferritin levels, 101

Trimonthly OC regimen, cost-effectiveness analysis, 263

TwoDay Algorithm, identify fertile window, 65

Uterine activity, effect of estradiol and antiestrogens, 111

Uterine bleeding, effect of mefenamic acid, 25

Uterine myomas, effect of levonorgestrel-releasing IUS, 51

Uterine perforation, anchored IUD, 55

Uterine receptivity, effect of mifepristone (rabbit), 309

Vaginal epithelium, effect of DMPA, 15

Vaginal ring, progesterone-releasing, 9

Vaginal tolerance, Acid-buffering bioadhesive gel, 361
nonoxynol-9, 361

X
T
D
9

